Between Scylla and Charybdis: Antipsychotic and other psychotropic medications in older nursing home residents

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 7, 2011, Pages 778-779

  Pollock, Bruce G ^a,b   Mulsant, Benoit H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; COGNITIVE DEFECT; DELIRIUM; DEMENTIA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ELDERLY CARE; HUMAN; NOTE; NURSING HOME PATIENT; PSYCHOSIS; RESTLESSNESS; SEDATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VOCALIZATION;

EID: 79955144105     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.110348     Document Type: Note

References (13)

1. Ballard C, Corbett A, Chitramohan R, et al. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. Curr Opin Psychiatry 2009;22:532-40.
2. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38. (Pubitemid 44547805)
3. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43. (Pubitemid 41464695)
4. Huybrechts KF, Rothman KJ, Silliman RA, et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 2011;183:E411-9.
5. Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007;164:1568-76. (Pubitemid 350069737)
6. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41. (Pubitemid 41713745)
7. Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing 2011;40:23-9.
8. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12. (Pubitemid 38489892)
9. Ganguli M, Dodge HH, Mulsant BH. Rates and predictors of mortality in an aging, rural, community based cohort: the role of depression. Arch Gen Psychiatry 2002;59:1046-52.
10. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163:2716-24. (Pubitemid 37517412)
11. Johnson EM, Whyte E, Mulsant BH, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 2006;14:796-802. (Pubitemid 44380072)
12. Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 2005; 45: 1106-22.
13. Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007;15:942-52.